Onconova Therapeutics selects Acurian’s Clinical Trial Liaison (CTL) Service for the ONTIME trial

HORSHAM, Pa.--(BUSINESS WIRE)-- Acurian, Inc., a leading, full-service provider of global patient recruitment and retention solutions, announced today that it has signed an agreement with Onconova Therapeutics®, Inc., a private biopharmaceutical company located in Newtown, PA and Pennington, NJ.

Acurian will provide Clinical Trial Liaison Services (CTL) as city-specific resources. CTLs have deep practical oncology knowledge and research-specific experience. They will provide Onconova with referral physician support within the surrounding area of clinical investigators for the “ONTIME” trial (ON 01910.Na Trial in Myelodysplastic Syndrome), which is now being conducted in more than 50 sites in the U.S. and Europe.

ONTIME is presently recruiting patients across the U.S. and the Acurian CTLs will assist with area Hematology/Oncology awareness of ONTIME across five cities. These highly experienced professionals work among local community and institutional practices to raise overall trial awareness, and to build relationships with local physicians, advocacy groups, tumor boards, and medical and nursing societies.

“Acurian is grateful for this opportunity to assist Onconova with the ONTIME trial. Our CTLs will support this important assignment to the benefit of healthcare providers and patients with MDS,” said Edwin Watson, Senior Director, Oncology at Acurian. “We are aware that only three percent of cancer patients in the United States participate in oncology trials, while many may benefit from expanded participation,” he added.

Onconova focuses on targeting cancer, while protecting healthy cells. The company is developing targeted anti-cancer therapeutics by taking advantage of increased understanding of how normal cells change to become cancerous, and exploiting differences in cell cycle regulation of normal versus cancer cells.

About Acurian

Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary patient panel of over 65 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials, all while supporting investigator sites with services to maximize the randomization potential of every referred patient.

Since 1998, Acurian has supported over 450 protocols for more than 100 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.

About ONTIME

ONTIME (ON 01910.Na Trial In Myelodysplastic Snydrome) is a Phase III, multi-center, randomized, monotherapy trial comparison of rigosertib (ON 01910.Na) to best supportive care, designed to determine the efficacy and safety of rigosertib in higher-risk MDS patients with excess blasts (5% to 30% bone marrow blasts), who are refractory, intolerant to, or have relapsed after azacitidine or decitabine treatment. The trial is enrolling MDS patients in both the United States and Europe. The ClinicalTrials.gov identifier for ONTIME is NCT01241500.



CONTACT:

Acurian, Inc.
Scott Connor, Vice President, Marketing
215-323-9028
[email protected]

KEYWORDS:   United States  North America  New Jersey  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.